Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient.
To explore the causes of complications in pregnant women with systemic lupus erythematosus (SLE), we prospectively evaluated 34 pregnancies in 28 SLE patients, and 2 additional pregnancies in patients with lupus anticoagulant and positive antinuclear antibody, but no other manifestations of SLE. Nineteen pregnancies (55%) were complicated by marked proteinuria, thrombocytopenia, and/or lupus anticoagulant. Hypocomplementemia occurred in 18 pregnancies (52%). Neither thrombocytopenia-anticoagulant nor proteinuria was accompanied by an increase in antibody to double-stranded DNA or by clinical signs of active SLE. Antibody to Ro antigen did not predict fetal death. Both thrombocytopenia and proteinuria appeared abruptly during pregnancy and disappeared quickly after delivery. Fetal death was the result in 7 of 9 (77%) pregnancies in patients with anticoagulant, 6 of 10 (60%) in patients with thrombocytopenia, 6 of 18 (33%) in patients with hypocomplementemia, and 3 of 11 (27%) in patients with proteinuria. Twenty of 29 (68%) children were identified as male. The pathogenesis of hypocomplementemia was evaluated by a new assay, C1s-C1 inhibitor complex, which is thought to measure rate of complement activation by the classical pathway. Most pregnant patients with low CH50 levels and proteinuria had normal levels of C1s-C1 inhibitor complex, whereas nonpregnant patients with equivalent proteinuria and hypocomplementemia had high levels, as did pregnant patients with hypocomplementemia who did not have SLE. Pregnant and nonpregnant hypocomplementemic patients with proteinuria had similar levels of C3 and C4. In pregnant patients with SLE, C1s-C1 inhibitor complex was independent of CH50; in nonpregnant patients a linear relationship between C1s-C1 inhibitor complex and CH50 was seen.(ABSTRACT TRUNCATED AT 250 WORDS)
D000974:Antibodies, Antinuclear; D000941:Antigens / Q000276:immunology; D001324:Autoantigens; D001779:Blood Coagulation Factors / Q000032:analysis / Q000037:antagonists & inhibitors; D003166:Complement Activating Enzymes / Q000378:metabolism; D003174:Complement C1 Inactivator Proteins / Q000097:blood; D003173:Complement C1s; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D003165:Complement System Proteins / Q000172:deficiency*; D005260:Female; D005313:Fetal Death / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000503:physiopathology; D016682:Lupus Coagulation Inhibitor; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology*; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins; D013921:Thrombocytopenia / Q000276:immunology*; D000099207:SS-A Antigen
D000974:Antibodies, Antinuclear; D000941:Antigens; D001324:Autoantigens; D001779:Blood Coagulation Factors; D003166:Complement Activating Enzymes; D003174:Complement C1 Inactivator Proteins; D003173:Complement C1s; D003176:Complement C3; D003181:Complement C4; D003165:Complement System Proteins; D016682:Lupus Coagulation Inhibitor; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins; D000099207:SS-A Antigen; C116006:RO60 protein, human